Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Gestational Diabetes Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for gestational diabetes experienced robust expansion historically and is projected to continue its upward trajectory, expanding from $9.11 billion in 2025 to $9.93 billion in 2026, reflecting a compound annual growth rate of 8.9%. This growth during the past period is largely due to several key factors including rising obesity trends, an increase in pregnancies among older women, the implementation of early screening for diabetes, advancements in prenatal care services, and a heightened awareness of complications associated with pregnancy.

The market for gestational diabetes is poised for significant expansion in the coming years, projected to reach $13.85 billion by 2030, driven by a compound annual growth rate of 8.7%. This projected increase during the forecast period is largely fueled by an escalating incidence of gestational diabetes, the proliferation of digital health monitoring solutions, enhancements in prenatal diagnostic capabilities, a heightened emphasis on preventative care for expectant mothers, and supportive healthcare policies. Key developments anticipated within this timeframe include a greater uptake of blood glucose monitoring systems, augmented utilization of insulin therapy for pregnant individuals, a growing emphasis on managing this condition through lifestyle modifications, the broadening of prenatal screening initiatives, and elevated awareness surrounding maternal health.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

Gestational Diabetes Market Development Factors: Which Trends Are Supporting Demand?

The expanding segment of the population classified as obese, characterized by a body mass index (BMI) of 30 or greater and signifying substantial body fat, is poised to be a significant catalyst for the expansion of the gestational diabetes market. This surge in obesity rates is attributable to a confluence of factors including predominantly inactive lifestyles, a greater reliance on energy-dense, processed food items, inherent genetic tendencies, and restricted availability of nutritious food choices and physical activity venues. The management of gestational diabetes holds particular importance for this demographic, given their heightened susceptibility to insulin resistance and accelerated weight gain during pregnancy, scenarios that can precipitate adverse outcomes for both the expectant mother and the developing fetus if not properly addressed. Illustrating this trend, data from the Office for Health Improvement and Disparities, a UK governmental organization, indicated that in England, a notable 64.5% of individuals aged 18 and above were either overweight or obese between 2023 and 2024, a slight increase from the 64.0% recorded in the preceding year (2022-2023). Consequently, the growing prevalence of obesity is a primary determinant in the upward trajectory of the gestational diabetes market.

Gestational Diabetes Market Segment Landscape: Which Areas Lead Market Development?

The gestational diabetes market covered in this report is segmented –

1) By Type: Type A1, Type A2, Other Types

2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment

3) By Administration: Oral, Intravenous, Other Administrations

4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers

Subsegments:

1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes

2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes

3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications

Gestational Diabetes Market Transformation Trends: Which Innovations Are Driving Change?

Within the gestational diabetes market, leading enterprises are prioritizing the creation of cutting-edge solutions, specifically diagnostic kits, to facilitate swift, precise, and user-friendly early identification of the condition; these kits serve as vital medical instruments for quantifying blood sugar levels and pinpointing instances of impaired glucose tolerance in expectant mothers, thereby supporting prompt diagnosis and effective management. Illustratively, in August of 2024, DirectSens GmbH, a biotechnology firm headquartered in Austria, introduced the XpressGT RUO kit, a diagnostic device engineered for the detection of gestational diabetes, alongside conditions like endometriosis, insulin resistance, and liver ailments, which gauges 2-hydroxybutyrate (2-HB) concentrations in venous blood with high accuracy; this metabolite, a natural byproduct of liver activity, can escalate due to reductive stress, a factor implicated in numerous endocrine and obesity-related health issues, including insulin resistance, and the kit’s compatibility with any standard clinical analyzer enables the generation of results within an impressive 8-minute timeframe, presenting a remarkably expedient diagnostic capability.

Gestational Diabetes Market Industry Leaders And Market Competition

Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd

Access The Complete Gestational Diabetes Market Report:

https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

Gestational Diabetes Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the gestational diabetes market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model